Literature DB >> 32544099

IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19.

Miao Luo1, Jing Liu2, Weiling Jiang1, Shuang Yue1, Huiguo Liu1, Shuang Wei1.   

Abstract

BACKGROUNDFatal cases of COVID-19 are increasing globally. We retrospectively investigated the potential of immunologic parameters as early predictors of COVID-19.METHODSA total of 1018 patients with confirmed COVID-19 were enrolled in our 2-center retrospective study. Clinical feature, laboratory test, immunological test, radiological findings, and outcomes data were collected. Univariate and multivariable logistic regression analyses were performed to evaluate factors associated with in-hospital mortality. Receiver operator characteristic (ROC) curves and survival curves were plotted to evaluate their clinical utility.RESULTSThe counts of all T lymphocyte subsets were markedly lower in nonsurvivors than in survivors, especially CD8+ T cells. Among all tested cytokines, IL-6 was elevated most significantly, with an upward trend of more than 10-fold. Using multivariate logistic regression analysis, IL-6 levels of more than 20 pg/mL and CD8+ T cell counts of less than 165 cells/μL were found to be associated with in-hospital mortality after adjusting for confounding factors. Groups with IL-6 levels of more than 20 pg/mL and CD8+ T cell counts of less than 165 cells/μL had a higher percentage of older and male patients as well as a higher proportion of patients with comorbidities, ventilation, intensive care unit admission, shock, and death. Furthermore, the receiver operating curve of the model combining IL-6 (>20 pg/mL) and CD8+ T cell counts (<165 cells/μL) displayed a more favorable discrimination than that of the CURB-65 score. The Hosmer-Lemeshow test showed a good fit of the model, with no statistical significance.CONCLUSIONIL-6 (>20 pg/mL) and CD8+ T cell counts (<165 cells/μL) are 2 reliable prognostic indicators that accurately stratify patients into risk categories and predict COVID-19 mortality.FundingThis work was supported by funding from the National Natural Science Foundation of China (no. 81772477 and 81201848).

Entities:  

Keywords:  Cytokines; Infectious disease; Pulmonology; T cells

Mesh:

Substances:

Year:  2020        PMID: 32544099      PMCID: PMC7406244          DOI: 10.1172/jci.insight.139024

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  23 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.

Authors:  Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter
Journal:  BMJ       Date:  2009-06-29

3.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

4.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice.

Authors:  Rudragouda Channappanavar; Anthony R Fehr; Rahul Vijay; Matthias Mack; Jincun Zhao; David K Meyerholz; Stanley Perlman
Journal:  Cell Host Microbe       Date:  2016-02-10       Impact factor: 21.023

5.  Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients.

Authors:  Jeffrey P Jacobs; Alfred H Stammers; James St Louis; J W Awori Hayanga; Michael S Firstenberg; Linda B Mongero; Eric A Tesdahl; Keshava Rajagopal; Faisal H Cheema; Tom Coley; Vinay Badhwar; Anthony K Sestokas; Marvin J Slepian
Journal:  ASAIO J       Date:  2020-07       Impact factor: 2.872

6.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

7.  Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection.

Authors:  Hyoung-Shik Shin; Yeonjae Kim; Gayeon Kim; Ji Yeon Lee; Ina Jeong; Joon-Sung Joh; Hana Kim; Eunjin Chang; Soo Yeon Sim; Jun-Sun Park; Dong-Gyun Lim
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

8.  Viruses detected by systematic multiplex polymerase chain reaction in adults with suspected community-acquired pneumonia attending emergency departments in France.

Authors:  D Das; H Le Floch; N Houhou; L Epelboin; P Hausfater; A Khalil; P Ray; X Duval; Y-E Claessens; C Leport
Journal:  Clin Microbiol Infect       Date:  2015-02-20       Impact factor: 8.067

9.  Effective treatment of severe COVID-19 patients with tocilizumab.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

10.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

View more
  46 in total

Review 1.  Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.

Authors:  Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
Journal:  Expert Rev Clin Immunol       Date:  2020-11-25       Impact factor: 4.473

2.  Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein.

Authors:  Pui Wang; Siu-Ying Lau; Shaofeng Deng; Pin Chen; Bobo Wing-Yee Mok; Anna Jinxia Zhang; Andrew Chak-Yiu Lee; Kwok-Hung Chan; Rachel Chun-Yee Tam; Haoran Xu; Runhong Zhou; Wenjun Song; Li Liu; Kelvin Kai-Wang To; Jasper Fuk-Woo Chan; Zhiwei Chen; Kwok-Yung Yuen; Honglin Chen
Journal:  Nat Commun       Date:  2021-05-13       Impact factor: 14.919

3.  Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic.

Authors:  Monty Montano
Journal:  AIDS Res Hum Retroviruses       Date:  2021-03-17       Impact factor: 1.723

Review 4.  T Cells: Warriors of SARS-CoV-2 Infection.

Authors:  Paola de Candia; Francesco Prattichizzo; Silvia Garavelli; Giuseppe Matarese
Journal:  Trends Immunol       Date:  2020-11-13       Impact factor: 16.687

5.  Lymphocyte blood levels that remain low can predict the death of patients with COVID-19.

Authors:  Hong-Jun Zhang; Gang-Qiang Qi; Xing Gu; Xiao-Yan Zhang; Yan-Feng Fang; Hong Jiang; Yan-Jun Zhao
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

6.  Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: A living systematic review and meta-analysis.

Authors:  Ana Karla G Melo; Keilla M Milby; Ana Luiza M A Caparroz; Ana Carolina P N Pinto; Rodolfo R P Santos; Aline P Rocha; Gilda A Ferreira; Viviane A Souza; Lilian D A Valadares; Rejane M R A Vieira; Gecilmara S Pileggi; Virgínia F M Trevisani
Journal:  PLoS One       Date:  2021-06-29       Impact factor: 3.240

7.  Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis.

Authors:  Farha Musharrat Noor; Md Momin Islam
Journal:  J Community Health       Date:  2020-12

8.  Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions.

Authors:  Arthur Eumann Mesas; Iván Cavero-Redondo; Celia Álvarez-Bueno; Marcos Aparecido Sarriá Cabrera; Selma Maffei de Andrade; Irene Sequí-Dominguez; Vicente Martínez-Vizcaíno
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

9.  Tempering Macrophage Plasticity for Controlling SARS-CoV-2 Infection for Managing COVID-19 Disease.

Authors:  Devinder Toor; Aklank Jain; Shivani Kalhan; Harmesh Manocha; Vivek Kumar Sharma; Payal Jain; Vishwas Tripathi; Hridayesh Prakash
Journal:  Front Pharmacol       Date:  2020-10-16       Impact factor: 5.810

10.  Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis.

Authors:  Ayat Zawawi; Abdallah Y Naser; Hassan Alwafi; Faisal Minshawi
Journal:  Front Immunol       Date:  2021-05-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.